about
Expression and mutational status of c-kit in small-cell lung cancer: prognostic relevance.Acute major airway injuries: clinical features and management.Four thymus-related syndromes in a case of invasive thymoma.Historical perspectives: The evolution of the thymic epithelial tumors staging system.Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors.PTPN22 and myasthenia gravis: replication in an Italian population and meta-analysis of literature data.Pleural recurrence of thymoma: surgical resection followed by hyperthermic intrathoracic perfusion chemotherapy†.Percutaneous radiofrequency ablation of lung tumours: results in the mid-term.P2X7 mRNA expression in non-small cell lung cancer: MicroRNA regulation and prognostic value.Surgery in the management of small cell lung cancer.Association of the DNMT3B -579G>T polymorphism with risk of thymomas in patients with myasthenia gravisEGFR and KRAS mutational analysis in a large series of Italian non-small cell lung cancer patients: 2,387 cases from a single center.Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancerPrognostic significance of osteopontin expression in early-stage non-small-cell lung cancer.A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma.Treatment with interleukin-2 in malignant pleural mesothelioma: immunological and angiogenetic assessment and prognostic impact.Gene-Specific Methylation Analysis in Thymomas of Patients with Myasthenia Gravis.Surgical treatment of stage III thymic tumors: a multi-institutional review from four Italian centers.Histo-cytological diagnostic accuracy in lung cancer.Expression status of candidate genes in mesothelioma tissues and cell lines.A common polymorphism within MSLN affects miR-611 binding site and soluble mesothelin levels in healthy people.Malignant pleural mesothelioma and mesothelial hyperplasia: A new molecular tool for the differential diagnosis.KIF5B/RET fusion gene analysis in a selected series of cytological specimens of EGFR, KRAS and EML4-ALK wild-type adenocarcinomas of the lung.EML4-ALK translocation in both metachronous second primary lung sarcomatoid carcinoma and lung adenocarcinoma: a case report.Induction therapy followed by surgical resection in Stage-III thimic epithelial tumors: Long-term results from a multicentre analysis of 108 cases.A pilot study of the role of TC-99 radionuclide in localization of pulmonary nodular lesions for thoracoscopic resection.Comparison of outcomes between neuroendocrine thymic tumours and other subtypes of thymic carcinomas: a joint analysis of the European Society of Thoracic Surgeons and the International Thymic Malignancy Interest Group.Transcollation® technique in the thoracoscopic treatment of primary spontaneous pneumothorax.Development of the international thymic malignancy interest group international database: an unprecedented resource for the study of a rare group of tumors.Does the World Health Organization histological classification predict outcomes after thymomectomy? Results of a multicentre study on 750 patients.Wedge resection and radiofrequency ablation for stage I nonsmall cell lung cancer.The multimodality treatment of thymic carcinoma.Small cell lung carcinoma (SCLC): the angiogenic phenomenon.Outcome of primary neuroendocrine tumors of the thymus: a joint analysis of the International Thymic Malignancy Interest Group and the European Society of Thoracic Surgeons databases.Association of thymoma and myasthenia gravis: oncological and neurological results of the surgical treatment.ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment.Advanced stage thymomas and thymic carcinomas: results of multimodality treatments.Pharmacokinetics of azithromycin in serum, bronchial washings, alveolar macrophages and lung tissue following a single oral dose of extended or immediate release formulations of azithromycin.A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors.Management of pleural recurrence after curative resection of thymoma.
P50
Q27824818-2B56EDB4-B525-42B8-938B-7C323E923731Q30681277-4DBF93EC-FE4C-411C-A5CB-263DD21853EFQ33377248-A4C71EE7-1024-4BD0-9376-40F6B599BC7DQ34039485-91A7701E-576E-4B64-B3D0-9D7489DF3B08Q34059518-C8914F0F-A06C-4EE1-80DB-33BAAF4C7197Q34111680-6F136615-79B0-4E14-B931-F9AF8A22E0ADQ34461961-828B454B-3D78-4766-9008-EB2E893CC2C7Q34567809-CBDB6955-AB59-4CB6-97B2-1A5A397EF17BQ34583795-88BC877F-740E-4B47-B272-4282EF759C82Q34745001-DB874066-2A2D-4205-A24B-B253758D4F41Q35049295-B35E3175-B453-4CA2-8180-3ABF3D01B049Q36066994-13B15D1E-B172-4F81-A6FF-9B50C163BC3AQ36080901-1DB71C1F-5305-49FF-8755-0B585DD0ED79Q36615218-21B2770A-8656-4D7F-A0E8-511D0345D8DCQ36644123-844EA587-C344-457E-87D4-07426F982EE8Q37457750-9210D5E1-5545-437D-9E53-E75C6CA2F162Q37534907-98F404BF-2C9B-4B70-9E3E-F9376870AB0FQ37824771-7AF25A16-A1AF-4BE6-9283-26245B8542CAQ38164052-9D50D3F1-CD85-4755-B19A-7FDB4E691856Q38899936-C942E91D-3DF4-406F-956B-294CA21A6CE1Q38936594-3F718593-BD54-4FC2-B074-F0FB9A9E9E60Q39195364-230CB414-ACDD-4EA5-AEF7-061161F920C9Q39377125-83E55F6E-DD26-486D-86AE-087DF9EDAC41Q39420886-949D0271-21D7-4289-ACE3-3F22C330A0A2Q39981145-B7174B76-3420-4BB8-A7AB-BFD639CDED88Q40759626-37FBEB85-3AD8-411D-921C-5881C40F3650Q40824315-EBDE8FF5-874C-4ED6-B1E8-05C31E7DD030Q41647248-09B5461C-1CF0-4D52-AC99-C3FC9FF0B38AQ41673890-D4AB0444-D7F8-49E4-965D-EACFED10240DQ42684598-F0089114-3915-4FED-AC69-05918FF14435Q43545933-0191B37B-1C40-43A8-81EF-71A071CE3559Q43601650-103A821B-7785-456A-A9C2-4FDEB07237FCQ44016800-52E2B57F-11CD-4835-80D8-429578A4429EQ44558782-C77406AD-8C46-429D-9F16-CB620CD7367CQ44819380-66F5D19C-DBDC-4D19-BCB3-B12A655F2FCBQ46144361-F2070B0D-74EF-4CBE-A9BC-C18CC03A8F36Q46512578-B6BFCD27-B14C-40F0-96C6-BB77D3903858Q46770344-125EE5E6-9106-4CD9-8F2D-7A6D5B65F21AQ47142579-08215EA4-B64D-43BF-B219-E8FE4E86D884Q50610978-6DA627D0-8D30-4B06-8494-178DD3DBCF51
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Marco Lucchi
@ast
Marco Lucchi
@en
Marco Lucchi
@es
Marco Lucchi
@nl
type
label
Marco Lucchi
@ast
Marco Lucchi
@en
Marco Lucchi
@es
Marco Lucchi
@nl
prefLabel
Marco Lucchi
@ast
Marco Lucchi
@en
Marco Lucchi
@es
Marco Lucchi
@nl
P106
P1153
56756235000
P21
P31
P496
0000-0001-9909-6820